

**Date: 09/11/2023**

|   |  |
|---|--|
| BSE Limited<br>Phiroze Jeejeebhoy Towers<br>Dalal Street<br>Mumbai - 400 001.<br><br>Script Code : 539872 | National Stock Exchange of India Limited<br>5 <sup>th</sup> Floor, Exchange Plaza,<br>Bandra Kurla Complex Bandra (East)<br>Mumbai-400051.<br><br>Script Code : BAJAJHCARE |
|---|--|

Dear Sir/Madam,

**Sub :** Outcome of Board Meeting & submission of Unaudited Financial Results for the quarter / half year ended September 30, 2023.

We hereby inform you that at the meeting of the Board of Directors of our Company held today i.e. 09<sup>th</sup> September, 2023 has considered and approved the following:

- The unaudited Financial Statements for the quarter/ half year ended September 30, 2023, as recommended by the Audit Committee; and

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, we enclose the following:

(i) Unaudited Financial Results for the quarter/half year ended September 30, 2023 along with limited review report;

- Appointment of Mr. Amit Rajan as Chief Technical Officer of the Company.

Pursuant to Para A of Schedule III of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023, is enclosed as Annexure 'A'.

The above information will also available on the Company's website at [www.bajajhealth.com](http://www.bajajhealth.com).

We wish to inform you that Board Meeting commenced today at 5.00 p.m. and concluded at 6.20 p.m.

Kindly take the same on record.

Thanking you,

**For and on behalf of Board of Directors  
of Bajaj Healthcare Limited**

**Aakash Keshari  
Company Secretary**

**Annexure-A**

**Disclosure pursuant to Para A of Part A of Schedule III of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 read with Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023**

**Brief profile of Mr. Amit Rajan**

| <b>Sr. No.</b> | <b>Details of Event(s) that Needs to be provided</b>                                 | <b>Particulars</b>  |
|----------------|--|---|
| <b>1.</b>      | Reason for Change Viz. Appointment   | Appointment of Mr. Amit Rajan as a Chief Technical Officer.   |
| <b>2.</b>      | Date of Appointment & Term of Appointment  | Appointment with immediate effect i.e 09 <sup>th</sup> September, 2023. Term of appointment is not applicable since he is in full time employment with the Company.   |
| <b>3.</b>      | Brief profile  | Mr. Amit Rajan is in the pharma regulations space with over two and half decades of Pharma regulatory Affairs & Technical experience. He has Successfully led and managed numerous interactions with health authorities like FDA, European Authorities (UKMHRA, EDQM, EMA), WHO as well as other global health authorities of South Africa, Australia, Brazil, Canada, Eastern Europe etc. to assure on-time submissions/ approvals of DMF, EDMF, CEP, MAA & ANDAs. He also participated in various proactive collaborations with health authorities to formulate efficient strategies to support sterile and non-sterile specific operations. He has advised several pharma companies on Technical & Regulatory affairs, based in India & China and is knowledgeable of company-specific strategies. In the past, he has worked with companies like Torrent, Sun, Ranbaxy, Hikal, Wockhardt, Alkem & Kopran at various positions including leadership roles. |
| <b>4.</b>      | Disclosure of relationships between directors (in case of appointment of a director) | Not Applicable.   |


**Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Bajaj Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Bajaj Healthcare Limited** ('the Company') for the quarter ended **30 September 2023** and the year to date results for the period 1 April 2023 to 30 September 2023, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, Delhi, Noida and Pune




Walker Chandiok & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

## Walker ChandioK & Co LLP

5. The review of unaudited quarterly financial results for the quarter and period ended 30 September 2022 and audit of financial results for the year ended 31 March 2023 included in the Statement was carried out and reported by Chaturvedi & Agrawal, Chartered accountants, who had expressed unmodified conclusion vide their review report dated 11 November 2022 and unmodified audit opinion vide their audit report dated 30 May 2023, respectively, whose reports have been furnished to us and which have been relied upon by us for the purpose of our review of the Statement. Our conclusion is not modified in respect of this matter.

**For Walker ChandioK & Co LLP**  
Chartered Accountants  
Firm Registration No: 001076N/N500013

  
Ashish Gupta  
Partner  
Membership No. 504662



**UDIN: 23504662BGWGHP9469**

Place: Delhi  
Date: 09 November 2023

**BAJAJ HEALTHCARE LIMITED**  
(CIN No. : L99999MH1993PLC071892)  
Statement of Unaudited Financial Results for the Quarter and Six Months Ended 30 September 2023

(Rs. In Lakhs Except for Earnings Per Share)

| Particulars   | Quarter Ended    |                   |                  | Six Months Ended  |                  | Year Ended        |
|---|------------------|-------------------|------------------|-------------------|------------------|-------------------|
|   | 30 Sept 2023     | 30 June 2023      | 30 Sept 2022     | 30 Sept 2023      | 30 Sept 2022     | 31 March 2023     |
|   | (Unaudited)      | (Unaudited)       | (Unaudited)      | (Unaudited)       | (Unaudited)      | (Audited)         |
| <b>A. Continuing Operations</b>   |                  |                   |                  |                   |                  |                   |
| <b>I. Revenue from operations</b>   | 10,120.96        | 12,973.68         | 19,532.10        | 23,094.64         | 35,911.31        | 64,579.61         |
| <b>II. Other Income</b>   | 121.71           | 21.81             | 12.93            | 143.52            | 79.84            | 158.98            |
| <b>III. Total Income (I+II)</b>   | <b>10,242.67</b> | <b>12,995.49</b>  | <b>19,545.03</b> | <b>23,238.16</b>  | <b>35,991.15</b> | <b>64,738.59</b>  |
| <b>IV. Expenses</b>   |                  |                   |                  |                   |                  |                   |
| (a) Cost of materials consumed  | 5,102.32         | 7,612.58          | 13,926.45        | 12,714.90         | 25,910.87        | 40,766.42         |
| (b) Changes in Inventories of Finished Goods and Work in Progress                 | (617.01)         | (119.61)          | (1,645.39)       | (736.62)          | (3,443.37)       | (2,488.20)        |
| (c) Employee benefits expense   | 1,111.52         | 1,046.46          | 1,179.24         | 2,157.98          | 2,128.33         | 4,231.83          |
| (d) Finance Costs   | 826.38           | 875.08            | 364.41           | 1,701.46          | 622.46           | 1,756.10          |
| (e) Depreciation and amortisation expense   | 666.01           | 630.73            | 399.97           | 1,296.74          | 808.42           | 1,720.82          |
| (f) Other expenses  | 2,629.09         | 2,259.78          | 2,628.11         | 4,888.87          | 5,425.10         | 10,933.41         |
| <b>Total Expenses</b>   | <b>9,718.31</b>  | <b>12,305.02</b>  | <b>16,852.79</b> | <b>22,023.33</b>  | <b>31,451.81</b> | <b>56,920.38</b>  |
| <b>V. Profit before Tax from Continuing Operations</b>                            | <b>524.36</b>    | <b>690.47</b>     | <b>2,692.24</b>  | <b>1,214.83</b>   | <b>4,539.34</b>  | <b>7,818.21</b>   |
| <b>VI. Tax Expense</b>  |                  |                   |                  |                   |                  |                   |
| (a) Current tax   | -                | -                 | 573.00           | -                 | 999.00           | 1,572.00          |
| (b) Earlier Years   | -                | -                 | -                | -                 | -                | 63.76             |
| (c) Deferred Tax Charge / (Credit)  | 12.04            | (12.18)           | (8.74)           | (0.14)            | (22.81)          | (170.79)          |
| <b>Total Tax Expenses</b>   | <b>12.04</b>     | <b>(12.18)</b>    | <b>564.26</b>    | <b>(0.14)</b>     | <b>976.19</b>    | <b>1,464.97</b>   |
| <b>VII. Profit after Tax from Continuing Operations</b>                           | <b>512.32</b>    | <b>702.65</b>     | <b>2,127.98</b>  | <b>1,214.97</b>   | <b>3,563.15</b>  | <b>6,353.24</b>   |
| <b>B. Discontinued Operations</b>   |                  |                   |                  |                   |                  |                   |
| <b>VIII. Loss before Tax from Discontinued Operations</b>                         | <b>(970.40)</b>  | <b>(5,686.47)</b> | <b>(490.44)</b>  | <b>(6,656.87)</b> | <b>(721.96)</b>  | <b>(1,996.57)</b> |
| <b>IX. Tax Expense / (Credit) of Discontinued Operations</b>                      | <b>(111.99)</b>  | <b>(162.66)</b>   | <b>1.67</b>      | <b>(274.65)</b>   | <b>3.44</b>      | <b>54.24</b>      |
| <b>X. Loss after Tax from Discontinued Operations</b>                             | <b>(858.41)</b>  | <b>(5,523.81)</b> | <b>(492.11)</b>  | <b>(6,382.22)</b> | <b>(725.40)</b>  | <b>(2,050.81)</b> |
| <b>XI. Profit / (Loss) for the period / year (VII + X)</b>                        | <b>(346.09)</b>  | <b>(4,821.16)</b> | <b>1,635.87</b>  | <b>(5,167.25)</b> | <b>2,837.75</b>  | <b>4,302.43</b>   |
| <b>XII. Other comprehensive Income</b>  |                  |                   |                  |                   |                  |                   |
| <b>Continuing Operations</b>  |                  |                   |                  |                   |                  |                   |
| (i) Items that will not be reclassified to profit or loss                         | 17.07            | -                 | -                | 17.07             | -                | 42.67             |
| (ii) Income tax relating to items that will not be reclassified to profit or loss | (4.30)           | -                 | -                | (4.30)            | -                | (10.74)           |
| <b>Total Other Comprehensive Income from Continuing Operations</b>                | <b>12.77</b>     | <b>-</b>          | <b>-</b>         | <b>12.77</b>      | <b>-</b>         | <b>31.93</b>      |
| <b>Discontinued Operations</b>  |                  |                   |                  |                   |                  |                   |
| (i) Items that will not be reclassified to profit or loss                         | -                | -                 | -                | -                 | -                | -                 |
| (ii) Income tax relating to items that will not be reclassified to profit or loss | -                | -                 | -                | -                 | -                | -                 |
| <b>Total Other Comprehensive Income from Discontinued Operations</b>              | <b>-</b>         | <b>-</b>          | <b>-</b>         | <b>-</b>          | <b>-</b>         | <b>-</b>          |
| <b>XIII. Total Comprehensive Income for the Period / Year</b>                     | <b>(333.32)</b>  | <b>(4,821.16)</b> | <b>1,635.87</b>  | <b>(5,154.48)</b> | <b>2,837.75</b>  | <b>4,334.36</b>   |
| <b>XIV. Paid-up Equity Share Capital (Face Value Rs. 5/-)</b>                     | <b>1,379.92</b>  | <b>1,379.92</b>   | <b>1,379.92</b>  | <b>1,379.92</b>   | <b>1,379.92</b>  | <b>1,379.92</b>   |
| <b>XV. Other Equity</b>   |                  |                   |                  |                   |                  | <b>35,389.02</b>  |
| <b>XVI. EPS (Not Annualised except for the Year Ended 31 March 2023)</b>          |                  |                   |                  |                   |                  |                   |
| <b>Continuing Operations</b>  |                  |                   |                  |                   |                  |                   |
| (a) Basic & Diluted (in Rs.)  | 1.86             | 2.55              | 7.71             | 4.40              | 12.91            | 23.02             |
| <b>Discontinued Operations</b>  |                  |                   |                  |                   |                  |                   |
| (a) Basic & Diluted (in Rs.)  | (3.11)           | (20.02)           | (1.78)           | (23.13)           | (2.63)           | (7.43)            |
| <b>Total Operations</b>   |                  |                   |                  |                   |                  |                   |
| (a) Basic & Diluted (in Rs.)  | (1.25)           | (17.47)           | 5.93             | (18.73)           | 10.28            | 15.59             |

**Note :**

- a) The above financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 09 November 2023 and subjected to limited review carried out by Statutory Auditors who have expressed unmodified review conclusion.
- b) The above unaudited financial results for the Quarter and Half Year Ended 30 September 2023 have been prepared in accordance with the Indian Accounting Standards (IND AS) notified under Section 133 of the Companies Act, 2013 (Act) read with relevant rules-Companies (Indian Accounting Standards) Rules, 2015 as amended, other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India.
- c) The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company identified only one reportable segment i.e. Pharmaceuticals.
- d) The Company has elected to exercise the option permitted under section 115BAA of the Income-tax Act, 1961. Accordingly, the Company has recognized Provision for Income Tax and re-measured its Deferred Tax Assets / Liabilities basis the rate prescribed in the said section. Company has not bifurcated the current tax expenses in continuing operations and discontinued operations as there is a taxable loss for the Company as a whole.
- e) The Board of Directors in their meeting held on 28 June 2023 approved to sale/disposal of undertaking/unit(s) on going concern basis, situated at plot no. N-92, L-9/3, T-30, MIDC Tarapur, Taluka- Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D-2/CH/42 & D-2/CH/43 Dahej industrial area, GIDC, Bharuch, Gujarat (which were acquired under SARFAESI ACT, 2002 from Sarasvat Bank) and plot no. E-62 and E-63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. Approval of shareholders has been obtained vide postal ballot. The management has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale/disposal under Ind AS 105 ("Non-current Assets Held for Sale and Discontinued Operations"). The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Considering these assets are held for sale, the assets have been recorded at their fair value on the date these assets has been classified as held for sale.

**The financial information from discontinued operations:**


| Particulars  | Quarter Ended |              |              | Six Months Ended |              | Year Ended    |
|--|---------------|--------------|--------------|------------------|--------------|---------------|
|  | 30 Sept 2023  | 30 June 2023 | 30 Sept 2022 | 30 Sept 2023     | 30 Sept 2022 | 31 March 2023 |
|  | (Unaudited)   | (Unaudited)  | (Unaudited)  | (Unaudited)      | (Unaudited)  | (Audited)     |
| Total Income (A)   | 629.90        | 690.21       | 557.50       | 1,320.11         | 1,385.26     | 2,750.37      |
| Total Expenses (B)                                       | 1,600.30      | 6,376.68     | 1,047.94     | 7,976.98         | 2,107.22     | 4,746.95      |
| Loss before Tax from Discontinued Operations (C = A - B) | -970.40       | -5,686.47    | -490.44      | -6,656.87        | -721.96      | -1,996.58     |
| Tax Expense / (Credit) from Discontinued Operations (D)  | -111.99       | -162.66      | 1.67         | -274.65          | 3.44         | 54.24         |
| Loss after Tax from Discontinued Operations (E = C - D)  | -858.41       | -5,523.81    | -492.11      | -6,382.22        | -725.40      | -2,050.82     |

Date : 09 November 2023  
Place : Thane



For and on Behalf of the Board  
For Bajaj Healthcare Limited

Mr. Salankumar R Bajaj  
D.No.: 00225950  
Chairman and Managing Director



# BAJAJ HEALTHCARE LIMITED

( CIN No. : L99999MH1993PLC072892 )

Unaudited Balance Sheet As At 30 September 2023

(Rs in Lakhs)


| Particulars |   | As at<br>30.09.2023 | As at<br>31.03.2023 |
|-------------|---|---------------------|---------------------|
|             |   | (Unaudited)         | (Audited)           |
| <b>A</b>    | <b>ASSETS</b>   |                     |                     |
| 1           | <b>Non-current assets</b>                                 |                     |                     |
|             | (a) Property Plant & Equipment                            | 24,307.50           | 36,568.81           |
|             | (b) Capital work-In-progress                              | 1,392.79            | 2,034.32            |
|             | (c) Intangible Assets Under Development                   | 161.48              | 138.56              |
|             | (d) Financial Assets                                      |                     |                     |
|             | (i) Investments   | 0.33                | 0.33                |
|             | (ii) Other Financial assets                               | 959.76              | 983.70              |
|             | (e) Deferred Tax Assets (Net)                             | 220.00              | -                   |
|             | <b>Total Non-current assets</b>                           | <b>27,041.86</b>    | <b>39,725.72</b>    |
| 2           | <b>Current assets</b>                                     |                     |                     |
|             | (a) Inventories   | 20,279.00           | 20,878.67           |
|             | (b) Financial Assets                                      |                     |                     |
|             | (i) Trade receivables                                     | 21,991.90           | 22,741.27           |
|             | (ii) Cash and cash equivalents                            | 551.46              | 1,772.04            |
|             | (iii) Bank Balance other than (ii) above                  | 482.40              | 150.88              |
|             | (iv) Other Financial assets                               | 90.36               | 460.00              |
|             | (c) Other Current assets                                  | 4,268.66            | 4,417.61            |
|             | <b>Total Current assets</b>                               | <b>47,663.78</b>    | <b>50,420.47</b>    |
|             | Asset Held for Sale                                       | 9,085.83            | -                   |
|             | <b>TOTAL ASSETS</b>                                       | <b>83,791.47</b>    | <b>90,146.19</b>    |
| <b>B</b>    | <b>EQUITY AND LIABILITIES</b>                             |                     |                     |
| 1           | <b>Equity</b>   |                     |                     |
|             | (a) Equity Share Capital                                  | 1,379.92            | 1,379.92            |
|             | (b) Other Equity  | 30,234.56           | 35,389.02           |
|             | <b>Total Equity</b>                                       | <b>31,614.48</b>    | <b>36,768.94</b>    |
| 2           | <b>Non-Current Liabilities</b>                            |                     |                     |
|             | <b>Financial Liabilities</b>                              |                     |                     |
|             | (a) Borrowings  | 5,748.61            | 9,366.16            |
|             | (b) Lease Liabilities                                     | 66.71               | 75.50               |
|             | (c) Provisions  | 286.70              | 279.12              |
|             | (d) Deferred Tax Assets (Net)                             | -                   | 50.49               |
|             | <b>Total Non-Current Liabilities</b>                      | <b>6,102.02</b>     | <b>9,771.27</b>     |
| 3           | <b>Current Liabilities</b>                                |                     |                     |
|             | (a) Financial Liabilities                                 |                     |                     |
|             | (i) Borrowings  | 29,862.13           | 32,066.84           |
|             | (ii) Lease Liabilities                                    | 17.13               | 15.87               |
|             | (iii) Trade payables                                      | 8,122.31            | 8,475.29            |
|             | (iv) Other Financial liabilities                          | 1,709.65            | 1,394.67            |
|             | (b) Other Current Liabilities                             | 184.17              | 218.99              |
|             | (c) Provisions  | 22.46               | 25.57               |
|             | (d) Current Tax Liabilities                               | 1,337.18            | 1,408.75            |
|             | <b>Total Current Liabilities</b>                          | <b>41,255.03</b>    | <b>43,605.98</b>    |
|             | Liabilities directly associated with Assets held for sale | 4,819.94            | -                   |
|             | <b>TOTAL - EQUITY AND LIABILITIES</b>                     | <b>83,791.47</b>    | <b>90,146.19</b>    |



Date: 09 November 2023  
Place: Thane

By Order of the Board  
For Bajaj Healthcare Limited

Mr. Sajankumar R Bajaj  
D.No.: 00225950  
Chairman and Managing Director



**Bajaj Healthcare Limited**  
**Unaudited Cash Flow Statement for Six Months Ended 30 September 2023**  
**CIN: L99999MH1993PLC072892**

Amt ( Rs. In Lakhs)

| Sr No    | Particulars  | Period Ended 30 September |                   |
|----------|--|---------------------------|-------------------|
|          |  | 2023                      | 2022              |
| <b>A</b> | <b>CASH FLOW FROM OPERATING ACTIVITIES</b>                           |                           |                   |
|          | <b>(Loss)/Profit Before Tax from :</b>                               |                           |                   |
|          | Continuing Operations  | 1,214.83                  | 4,539.34          |
|          | Discontinuing Operations   | (6,656.87)                | (721.96)          |
|          | <b>Adjustments for:</b>  |                           |                   |
|          | Depreciation   | 1,679.51                  | 1,301.06          |
|          | Profit on sale of Assets   | (2.62)                    | (1.28)            |
|          | Interest and Finance Charges   | 2,127.01                  | 877.62            |
|          | Interest on Fixed Deposit  | (10.04)                   | (2.81)            |
|          | Provision for Employee Benefits and Leave Enchashment                | 43.75                     | 8.44              |
|          | Interest Income on Security Deposit                                  | (0.25)                    | (0.04)            |
|          | Loss on sale or impairment of Property, Plant and Equipment          | 4,358.91                  | -                 |
|          | Provision for Expected Credit Loss                                   | 56.14                     | 45.91             |
|          | <b>Operating Profit before Working Capital Changes</b>               | <b>2,810.37</b>           | <b>6,046.28</b>   |
|          | <b>Adjustments for:</b>  |                           |                   |
|          | (Increase)/Decrease In Inventories                                   | 599.67                    | (2,384.04)        |
|          | (Increase)Decrease In Trade Receivables                              | 693.23                    | (3,968.01)        |
|          | (Increase)/Decrease in Other current assets                          | 205.31                    | 356.37            |
|          | Increase /(Decrease) in non current and current liabilities          | (81.58)                   | (472.31)          |
|          | <b>Cash generated from operations</b>                                | <b>4,227.00</b>           | <b>(421.71)</b>   |
|          | Less : Income Tax Paid (Net of Refund)                               | (70.14)                   | (683.67)          |
|          | <b>Net Cash flow generated from / (used in) Operating activities</b> | <b>4,156.86</b>           | <b>(1,105.38)</b> |
| <b>B</b> | <b>CASH FLOW FROM INVESTING ACTIVITIES</b>                           |                           |                   |
|          | Purchase of Property, Plant & equipment / Capital Work-in-progress   | (2,248.94)                | (4,667.67)        |
|          | Sale Of Fixed Assets   | 2.07                      | 19.85             |
|          | Interest on Fixed Deposit  | 10.04                     | 2.81              |
|          | <b>Net Cash (used in) Investing activities</b>                       | <b>(2,236.83)</b>         | <b>(4,645.01)</b> |
| <b>C</b> | <b>CASH FLOW FROM FINANCING ACTIVITIES</b>                           |                           |                   |
|          | Increase /( Decrease) From Long Term Borrowing                       | -                         | 481.35            |
|          | Proceeds from Long Term Borrowing                                    | 1,530.00                  | -                 |
|          | Repayment of Long Term Borrowing                                     | (1,562.99)                | -                 |
|          | Increase /( Decrease) Of Short Term Borrowing From Bank              | (968.02)                  | 7,429.87          |
|          | Increase /( Decrease) Of Borrowing From Director & Inter corpoates   | (1.30)                    | (131.74)          |
|          | Interest paid  | (2,127.01)                | (877.63)          |
|          | Payment of Lease Liabilities   | (11.29)                   | -                 |
|          | <b>Net Cash (used in)/generated from Financing activities</b>        | <b>(3,140.61)</b>         | <b>6,901.85</b>   |
|          | <b>Net generated / (used) in Cash &amp; Cash Equivalents (A+B+C)</b> | <b>(1,220.58)</b>         | <b>1,151.46</b>   |
|          | Cash and Cash equivalents as at Beginning of the period              | 1,772.04                  | 197.50            |
|          | Cash and Cash equivalents as at End of the period                    | 551.46                    | 1,348.96          |



Date : 09 November 2023  
Place: Thane

For and on behalf of the Board  
of Bajaj Healthcare Ltd

Mr. Sajankumar R Bajaj  
D.No.: 00225950  
Chairman and Managing Director

